OMF: Stanford Genome Technology Center Applies to NIH

[Eagles]

OMF: Stanford Genome Technology Center Applies to NIH

https://www.omf.ngo/2019/06/24/sgtc-applies-to-nih/

The Stanford Genome Technology Center (SGTC), under the direction of Ronald W. Davis, PhD, has submitted several RO1 grant applications to NIH to continue and scale up several projects that OMF is funding. Below are descriptions of the newest proposals.

By Ronald W. Davis, PhD

We recently submitted two NIH R01 applications, one from Stanford (PI: Ron Davis) that focuses on the RBC deformability assay and one by Rahim Esfandyarpour from UC Irvine on developing the nanoneedle for higher throughput. Both grants are using the OMF-funded patient sample collection and processing done at the SGTC under a Stanford IRB approved protocol. They are an extension of the foundational work that has been funded by OMF...

 

[rvallee]

NIH demanded hypothesis-testing from senior researchers working at world-class facilities. They don't always demand that, they could have set aside exploratory research budgets, but they demanded it here.

Here it is. Let's say whether the goalposts will move once more.

 

[theJOYdecision]

NIH demanded hypothesis-testing from senior researchers working at world-class facilities. They don't always demand that, they could have set aside exploratory research budgets, but they demanded it here.

Here it is. Let's say whether the goalposts will move once more.

OMF have only gained in prestige over time. They’ve engaged a growing audience. Patients and caregivers have got bolder in standing together and standing for ourselves. Some members of the media have become more sympathetic. We have an ally right in the CNN. If the NIH shifts the goalposts I suggest we make sure there’s hell to pay.

 

[Cinders66]

OMF: Stanford Genome Technology Center Applies to NIH

https://www.omf.ngo/2019/06/24/sgtc-applies-to-nih/

The Stanford Genome Technology Center (SGTC), under the direction of Ronald W. Davis, PhD, has submitted several RO1 grant applications to NIH to continue and scale up several projects that OMF is funding. Below are descriptions of the newest proposals.

By Ronald W. Davis, PhD

We recently submitted two NIH R01 applications, one from Stanford (PI: Ron Davis) that focuses on the RBC deformability assay and one by Rahim Esfandyarpour from UC Irvine on developing the nanoneedle for higher throughput. Both grants are using the OMF-funded patient sample collection and processing done at the SGTC under a Stanford IRB approved protocol. They are an extension of the foundational work that has been funded by OMF...

I think that it is great that they are trying to get as much funding as they can and seem to be really Trying to go at this from several angles simultaneously. There is urgency with this group and luckily for us that is combined with top scientists with connections and experience in moving research forward at a fitting speed. For me they are the beacon of hope.

There seems to have been a symposium at Harvard this month, written up by Chris Armstrong
https://www.omf.ngo/2019/06/24/me-cfs-harvard-collaboration-building-momentum
Harvard has funding from OMF I think.

 

[wigglethemouse]

I wonder where these 4 applications are in the process. Must be 5 months now. None appear in the NIH reporter tool . I wish the process was more transparent.

We recently submitted two NIH R01 applications,

one from Stanford (PI: Ron Davis) that focuses on the RBC deformability assay

and one by Rahim Esfandyarpour from UC Irvine on developing the nanoneedle for higher throughput.

Laurel Crosby has also submitted an NIH shared instrumentation grant for a new device that can assay mitochondrial function in white blood cells at very high throughput.

Nine months have passed since this application

This latter grant is in addition to her February submission this year of an R21 exploratory grant that will investigate the impact of organic mercury exposure on selenium bioavailability in ME/CFS.

Solve ME/CFS keep saying how important it is to have initial results from pilot studies when applying for larger grants at NIH. These all have promising pilot data............